AEAlba Erra

Alba Erra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alba Erra has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Concordance between direct and indirect measurements of free 25-OH vitamin D

    by Pilar Peris, Xavier Filella, Ana Monegal, Nuria Guañabens, Laura Foj, María Bonet, Dolors Boquet, Enrique Casado, Dacia Cerdá, Alba Erra, et al.


  • Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study

    by LabOscat Study Group, P. Peris, X. Filella, A. Monegal, N. Guañabens, L. Foj, M. Bonet, D. Boquet, E. Casado, D. Cerdá, et al.

    Summary Determination of different forms of 25-OHD (total, free and bioavailable) in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values T), DBP, albumin, PTH and bone formation (PINP,OC) and resorption (NTx,CTx) markers. Free(25-OHDF) and bioavailable (25-OHDB) serum 25-OHD levels were estimated by DBP and albumin determinations and also directly by ELISA (25-OHDF-2). We analysed threshold PTH values for the different forms of 25-OHD and the correlations and differences according to 25-OHDT levels T (15.4 ± 1.4 vs. 18.3 ± 2.7, p < 0.05) and 25OHDB values (1.7 ± 0.2 vs. 2.2 ± 0.09, p < 0.05). The different forms of 25OHD were significantly intercorrelated, with marginal correlations between PTH and 25-OHDT (r = −0.136, p = 0.082). Conclusions Determination of different forms of 25-OHD in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values <15 ng/ml would be more appropriate for defining this deficiency.


  • Nailfold capillaroscopic findings in primary Sjögren’s syndrome with and without Raynaud’s phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies

    by CapiCAT group, Hèctor Corominas, Vera Ortiz-Santamaría, Iván Castellví, Mireia Moreno, Rosa Morlà, Teresa Clavaguera, Alba Erra, Silvia Martínez-Pardo, Sergi Ordóñez, et al.

    The aim of this study was to assess nailfold capillaroscopic (NC) findings in patients with primary Sjögren’s syndrome (PSS) with and without Raynaud’s phenomenon (RP) as well as in the presence of positive anti-SSA/Ro and anti-SSB/La antibodies. Videocapillaroscopy was performed in 150 patients with PSS. Data collected included demographics, presence of RP, PSS symptoms, antinuclear antibodies, rheumatoid factor, anti-Ro, anti-La, anti-CCP, salivary scintigraphy, labial biopsy, and NC findings. RP was present in 32 % of PSS, keratoconjunctivitis sicca in 91 %, oral xerosis in 93 %, and skin or genital xerosis in 53 %. In patients with positive anti-SSA/Ro (75 %) and positive anti-SSB/La (40 %), NC showed normal findings in 53 % of cases and non-specific in 36 %. In patients with PSS, NC was normal in 51 % of cases and non-specific in 34 %. Scleroderma pattern was found in 14 patients. RP associated with PSS had non-specific capillaroscopy in 40 % of cases (p = 0.1). Pericapillary haemorrhages (p = 0.06) and capillary thrombosis (p = 0.2) were not increased, but more dilated capillaries were detected in 48 % of cases. Patients with positive anti-Ro and/or anti-La have not a distinct NC profile. Patients with RP associated with PSS had more dilated capillaries, but neither pericapillary haemorrhages nor capillary thrombosis was observed.


  • Open Access

    Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis

    by Maria Lopez-Lasanta, Antonio Julià, Joan Maymó, Benjamín Fernández-Gutierrez, Inmaculada Ureña-Garnica, Francisco J. Blanco, Juan D. Cañete, Mercedes Alperi-López, Alex Olivè, Héctor Corominas, et al.

    Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint damage. This study was performed to investigate the association between the genetic variation at IL6R gene and the severity of joint damage in RA. IL6R gene tagging SNPs (n = 5) were genotyped in a discovery group of 527 RA patients from 5 different university hospitals from Spain. For each marker, a linear regression analysis was performed using an additive model and adjusting for the years of evolution of the disease, autoantibody status, gender and age. Haplotypes combining the SNPs were also estimated and tested for association with the level of joint destruction. Using an independent cohort of 705 RA patients from 6 university hospitals we performed a validation study of the SNPs associated in the discovery phase. In the discovery group we found a highly significant association between IL6R SNP rs4845618 and the level of joint destruction in RA (P = 0.0058, P corrected = 0.026), and a moderate association with SNP rs4453032 (P = 0.02, P corrected = 0.05). The resulting haplotype from both SNPs was more significantly associated with joint damage (P = 0.0037, P corrected = 0.011). Using the validation cohort, we replicated the association between the two IL-6R SNPs with the degree of joint destruction in RA (P = 0.007 and P = 0.04, meta-analysis P = 0.00011 and P = 0.0021, respectively), and the haplotype association (P = 0.0058, meta-analysis P = 6.64 e-5). Genetic variation at IL6R gene is associated with joint damage in RA.


  • Open Access

    Is the recommended dose of leflunomide the best regimen to treat rheumatoid arthritis patients?

    by A. Erra, C. Tomas, P. Barcelo, M. Vilardell, S. Marsal

    Sir, The aim of this letter is to show our experience in the use of leflunomide (LFN) and express our opinion about the recommended dose [1, 2]. As far as we know, no data exist about a possible association between the loading dose and the presence of adverse events. Any new suggestion about the use of LFN should be appreciated, specially after the safety of this drug has been questioned.